PRECLINICAL MEDICATIONS SCREENING

开发治疗酒精使用障碍的药物是国家酒精滥用和酒精中毒研究所 (NIAAA) 的首要任务。 NIAAA 启动了一项临床前药物功效测试计划，以促进发现治疗酒精使用障碍的药物靶标和先导化合物。 该计划包括建立协调的基础设施和临床前实验室模型网络，可用于有效筛选潜在的治疗方法。该计划的目标是促进在标准化临床前模型中测试临床可用的药物疗法以及新颖的专有化合物，以捕获酒精使用障碍的关键要素。 临床前工作产生的信息被认为是药物开发过程中的关键步骤，旨在为后续工作提供信息，以推进人体实验室研究和对照临床试验中候选化合物的评估。 该合同用于在临床前模型中对参考化合物和感兴趣的化合物进行盲法功效测试。

Developing medications for treatment of alcohol use disorder is a high priority for the National Institute on Alcohol Abuse and Alcoholism (NIAAA). NIAAA has initiated a Preclinical Medication Efficacy Testing Program to foster discovery of medication targets and lead compounds to treat alcohol use disorder. This program included the establishment of a coordinated infrastructure and network of preclinical laboratory models that can be employed to effectively screen potential therapeutics. A goal of this initiative was to facilitate the testing of clinically available pharmacotherapies as well as novel proprietary compounds in standardized preclinical models that capture key elements of alcohol use disorder. Recognized as a critical step in the medications development process, information generated from this preclinical work is designed to both inform subsequent efforts to advance the evaluation of candidate compounds in human laboratory studies and controlled clinical trials. This contract is for the blind efficacy testing of reference compounds and compounds of interest in preclinical models.